ATX-MS-1467
Phase 2- Indications
- Multiple Sclerosis
Company intelligence / Profile preview
Apitope
Diepenbeek, Belgiumprnewswire.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Phase 2
01
Overview
Apitope developed a proprietary peptide-based immunotherapy platform (“apitopes®”) targeting the underlying immune dysregulation in autoimmune diseases. Lead program ATX-MS1467 showed positive safety and early efficacy signals in Phase I trials for multiple sclerosis and advanced to a Merck Serono-partnered Phase IIa trial. Other pipeline candidates target conditions such as Graves’ disease, hemophilia A with FVIII inhibitors, uveitis, myocarditis, and rheumatoid arthritis. The company’s approach aims to restore immune tolerance without global immunosuppression. In August 2021 it was acquired by Worg Pharmaceuticals; current development status may be under Worg’s management but legacy data shows several active programs at various stages from discovery through early clinical trials.
- Therapeutic areas
- CardiovascularOphthalmologyEndocrinologyImmunologyHematologyNeurology
- Modalities
- Peptide-based therapeutics (apitopes®)synthetic peptides
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Merck Serono (notably on MS program)European Commission funding on some projectsAbzena collaboration on manufacturing support for certain assets like ATX-F8–117
Beyond the preview
Go deeper on Apitope.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apitope.